Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 57

of 'Approach to the patient following treatment for breast cancer'

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators.
JAMA. 1994;271(20):1587.
OBJECTIVE: To assess prospectively the impact on survival and health-related quality of life of two follow-up protocols in patients with early breast cancer.
DESIGN: Randomized controlled clinical trial.
SETTING: Multicenter study involving 26 general hospitals in Italy.
PATIENTS: A consecutive sample of 1320 women younger than 70 years with stage I, II, and III unilateral primary breast cancer.
INTERVENTION: Patients were randomly assigned to an intensive surveillance, which included physician visits and performance of bone scan, liver echography, chest roentgenography, and laboratory tests at predefined intervals (n = 655), or to a control regimen (n = 665), in which patients were seen by their physicians at the same frequency but only clinically indicated tests were performed. Both groups received a yearly mammogram aimed at detecting contralateral breast cancer.
MAIN OUTCOME MEASURES: Primary end points were overall survival and health-related quality of life.
RESULTS: Compliance to the two follow-up protocols was more than 80%. At a median follow-up of 71 months, no difference was apparent in overall survival with 132 deaths (20%) in the intensive group and 122 deaths (18%) in the control group. No significant differences were apparent in time to detection of recurrence between the two groups. Measurements of health-related quality of life (ie, overall health and quality-of-life perception, emotional well-being, body image, social functioning, symptoms, and satisfaction with care) at 6, 12, 24, and 60 months of follow-up did not show differences by type of care received.
CONCLUSIONS: Results of this trial support the view that a protocol of frequent laboratory tests and roentgenography after primary treatment for breast cancer does not improve survival or influence health-related quality of life. Routine use of these tests should be discouraged.